Immunomodulating and antitumor activities of a synthetic lauroyltripeptide (RP 56 142).
Lauroyltripeptide (RP 56 142) (N2-[N-(N-lauroyl-L-alanyl)-gamma-D-glutamyl]-L,L-2,6-diaminopimelami c acid) was shown in murine models to activate several immune mechanisms involved in host defense against tumors. RP 56 142 induced macrophage activation and enhanced cytotoxicity of natural killer cells in spleen, blood, and liver. These activities correlated with prophylactic and therapeutic effects of RP 56 142 on artificial liver metastases of M5076 histiocytosarcoma. RP 56 142 alone did not inhibit spontaneous liver metastases of M5076 sarcoma; however, in combination with surgery or suboptimal doses of cisplatin, the compound exerted synergistic antimetastatic effects in the same model. These findings suggest that RP 56 142 could be used in cancer patients as an immunotherapeutic agent in combination with surgery, radiotherapy and/or conventional chemotherapy.
Fizames
C
C
Rhône-Poulenc Santé, Centre de Recherches de Vitry, France.
Poirier
J
J
Floc'h
F
F
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D007694:Killer Cells, Natural / Q000187:drug effects; D008099:Liver / Q000166:cytology; D008113:Liver Neoplasms / Q000556:secondary; D008264:Macrophages / Q000187:drug effects; D008297:Male; D051379:Mice; D009842:Oligopeptides / Q000494:pharmacology*; D010867:Pimelic Acids / Q000494:pharmacology*; D012513:Sarcoma, Experimental / Q000188:drug therapy; D013154:Spleen / Q000166:cytology
D000276:Adjuvants, Immunologic; D009842:Oligopeptides; D010867:Pimelic Acids; C024768:trimexautide; D002945:Cisplatin